Printer Friendly

DR. THOMAS H. ADAMS ELECTED TO LA JOLLA PHARMACEUTICAL BOARD

 DR. THOMAS H. ADAMS ELECTED TO LA JOLLA PHARMACEUTICAL BOARD
 SAN DIEGO, May 15 /PRNewswire/ -- La Jolla Pharmaceutical Co. announced today that Thomas H. Adams, Ph.D., chairman and chief executive officer of Genta Inc., was elected to La Jolla Pharmaceutical's (LJP) board of directors at its annual shareholder meeting.
 A pioneer and leader in biotechnology, Adams was instrumental in the launching of several important companies. He served as senior vice president of research and development at Hybritech and was a key contributor to its successful evolution prior to its acquisition by Eli Lilly. He then founded and became chairman and chief executive officer of Gen-Probe Inc., which was later acquired by Chugai Pharmaceuticals. Most recently, Adams was a founder of Genta, which he took public late last year. All three companies are leaders in their respective fields.
 "Dr. Adams brings much talent and pertinent experience to LJP. We intend to take full advantage of his expertise as the new products based on our tolerance technology move from R&D to the clinic," commented Joseph Stemler, the company's president.
 La Jolla Pharmaceutical Co. is developing products based on its proprietary antigen-polymer conjugate tolerogen technology to treat antibody-mediated diseases such as Lupus (SLE), Myasthenia Gravis, Graves' Disease, Rh Incompatibility and Stroke. The company is privately held and is headquartered in San Diego.
 -0- 5/15/92
 /CONTACT: Andrew Wiseman, Ph.D., of La Jolla Pharmaceutical Co., 619-452-6600/ CO: La Jolla Pharmaceutical Co. ST: California IN: MTC SU: PER


DM-JL -- SD001 -- 0571 05/15/92 08:19 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 15, 1992
Words:256
Previous Article:APPLE ANNOUNCES CROSSROADS 3 EDUCATION GRANTS RECIPIENTS
Next Article:QUAL-MED ANNOUNCES FIRST QUARTER RESULTS
Topics:


Related Articles
IDEC PHARMACEUTICALS PROMOTES PHILLIP SCHNEIDER TO VICE PRESIDENT, FINANCE AND ADMINISTRATION
LIDAK PHARMACEUTICALS ANNOUNCES RESIGNATIONS
LIDAK PHARMACEUTICALS ISSUES STATEMENT ON RESIGNATION OF DONALD E. MOSLER
DAVID ROBINSON JOINS BOARD OF DIRECTORS OF IDEC PHARMACEUTICALS
LIDAK PHARMACEUTICALS ELECTS NEW DIRECTOR
ANTONIO J. GRILLO-LOPEZ JOINS IDEC PHARMACEUTICALS AS VICE PRESIDENT, MEDICAL AND REGULATORY AFFAIRS
LIDAK PHARMACEUTICALS REAPPOINTS OFFICERS, APPROVES NEW CONTRACT WITH CEO AND APPOINTS CHAIRMAN
LA JOLLA PHARMACEUTICAL PROMOTES STEVEN B. ENGLE TO PRESIDENT
Steven Engle Elected Chairman of La Jolla Pharmaceutical Company

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters